TERBUTALINE SULFATE

Post-LOE

terbutaline sulfate

Hikma

ANDAINJECTIONINJECTABLE

Approved

May 2009

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

TERBUTALINE SULFATE (terbutaline sulfate) by Hikma is clinical pharmacology terbutaline sulfate injection is a beta-adrenergic receptor agonist. Approved for asthma. First approved in 2009.

Drug data last refreshed 19h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Terbutaline sulfate injection is a beta-adrenergic receptor agonist. In vitro and in vivo pharmacologic studies have demonstrated that terbutaline exerts a preferential effect on beta 2 ‑adrenergic receptors. While it is recognized that beta 2 -adrenergic receptors are the…

Worked on TERBUTALINE SULFATE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

TERBUTALINE SULFATE

Mechanism of Action

Indications (1)